Management von Herzklappenpatienten 2008

Zusammenfassung

Degenerative Aortenklappenstenosen und Mitralinsuffizienzen sind die häufigsten Herzklappenfehler in Mitteleuropa; ihre Prävalenz steigt mit Zunahme der Lebenserwartung stetig an. Trotz Zunahme des mittleren Patientenalters zum Interventionszeitpunkt sowie der Co-Morbidität ist die perioperative Sterblichkeit mit ca. 3,5 % in Deutschland konstant niedrig. Die Beschwerdesymptomatik ist für die Wahl des Interventionszeitpunktes wenig geeignet. Die Beurteilung der myokardialen Lastadaptation gelingt derzeit mit prognostischer Relevanz am besten durch Bestimmung der myokardialen Kontraktilitätsreserve. Durch fehlerhafte Beurteilung der myokardialen Adaptation erfolgen Klappeninterventionen auch heute noch oft zu spät, so dass die postoperative Prognose – insbesondere für Patienten mit Mitralinsuffizienz – eingeschränkt ist. Für viele Patienten mit Herzklappenfehlern und für alle Patienten nach Kunstklappenersatz besteht die Indikation zur Behandlung mit Vitamin-K-Antagonisten. Die Stabilität einer oralen Antikoagulation bestimmt weitgehend das Risiko von Embolien und Blutungen. Bei der Mehrzahl der Patienten ist eine Ziel-INR von 2,5 optimal. Das INR-Selbstmanagement senkt das Komplikationsrisiko um ca. 30 %.

Abstract

In Central Europe, the vast majority of patients with valvar heart disease today suffer from degenerative aortic valve stenosis or mitral regurgitation. Due to the aging population, the prevalence of both diseases is rapidly increasing. Despite older age at the time of intervention and more co-morbidities, perioperative mortality has been constantly low (about 3.5 % in Germany). Clinical symptoms reported by patients are often inappropriate to chose the optimal time for intervention. Myocardial contractility reserve is yet the most appropriate measure to assess myocardial adaption to the chronic pressure and/or volume overload. Awaiting myocardial maladaption is hampered by a significant worsening in prognosis. This is especially true for mitral regurgitation, where imaging techniques regularly fail to assess LV pump function due to the low left ventricular impedance. For patients with valvar heart disease requiring therapy with vitamin K antagonists, stability of oral anticoagulation therapy is essential to avoid thromboembolic as well as bleeding complications. For the majority of these patients, a target INR of 2.5 is optimal. INR point of care self management results in a more than 30 % reduction of adverse events.

Herzklappenfehler - Aortenstenose - Mitralinsuffizienz - Herzklappenersatz - Antikoagulation

valvar heart diseases - aortic valve stenosis - mitral regurgitation - heart valve replacement - anticoagulation

Literatur

• 1 Antithrombotic Management after Heart Valve Replacement: Results and Consequences of the GELIA study. Proceedings of an International Symposium held on March 30 – 31, 2001 in Bad Oeynhausen, Germany.  Eur Heart J Suppl. 2001;  3, Suppl Q
• 2 Bonow R O, Carabello B A, Chatterjee K. et al . ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.  J Am Coll Cardiol. 2006;  48 1-148
• 3 Gummert J F, Funkat A, Beckmann A. et al . Cardiac surgery in Germany during 2005. A report on behalf of the German Society for Thoracic and Cardiovascular Surgery.  Thorac Cardiovasc Surgeon. 2006;  54 362-371
• 4 Hering D, Piper C, Horstkotte D. Infuence of atypical symptoms and electrocardiographic signs of left ventricular hypertrophy or ST-segment/T-wave abnormalities on the natural history of otherwise asymptomatic adults with moderate to severe aortic stenosis: preliminary communication.  J Heart Valve Dis. 2004;  13 182-187
• 5 Horstkotte D. Antithrombotische Therapie nach Herzklappenersatz.  Z Kardiol. 1998;  87,Suppl 4
• 6 Horstkotte D, Piper C, Wiemer M, Schultheiß H P. Management von Patienten mit Aortenklappenstenosen.  Herz. 1998;  23 434-440
• 7 Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease.  J Thrombosis and Thrombolysis. 1998;  5 S19-S24
• 8 Huth C, Friedl A, Rost A. for the GELIA Study Investigator Group . Intensity of oral anticoagulation after implantation of St.- Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4).  Eur Heart J Suppl. 2001;  3 (Suppl Q) Q33-Q38
• 9 Kalmar P, Irrgang E. Cardiac surgery in the Federal Republic of Germany during 1990. A report by the German Society for Thoracic and Cardiovascular Surgery.  Thorac Cardiovasc Surgeon. 1991;  39 167-169
• 10 Kalmar P, Irrgang E. Cardiac surgery in Germany during 1995. A report by the German Society for Thoracic and Cardiovascular Surgery.  Thorac Cardiovasc Surgeon. 1996;  44 161-164
• 11 Kalmar P, Irrgang E. Cardiac surgery in Germany during 2000. A report by the German Society for Thoracic and Cardiovascular Surgery.  Thorac Cardiovasc Surgeon. 2000;  48 XXXIII-XXXVIII
• 12 Miche E, Bogunovic N, Fassbender D. et al . Predictors of unsuccessful outcome after percutaneous mitral valvotomy including a new echocardiographic scoring system.  J Heart Valve Dis. 1996;  5 430-35
• 13 Neumayer U, Schmidt H K, Fassbender D. et al . Early (three-month) results of percutaneous mitral valvotomy with the Inoue balloon in 1,123 consecutive patients comparing various age groups.  Am J Cardiol. 2002;  90 190-193
• 14 Piper C, Bergemann R, Schulte H D. et al . Can progression of valvar aortic stenosis be predicted accurately?.  Ann Thorac Surg. 2003;  76 676-80
• 15 Piper C, Horstkotte D. State of the Art in Anticoagulation Management.  J Heart Valve Dis. 2004;  13 (Suppl 1) S76-S80
• 16 Piper C, Schultheiss H P, Akdemir D. et al . Remodeling of the cardiac extracellular matrix differs between volume and pressure-overloaded ventricles and is specific for each heart valve lesion.  J Heart Valve Dis. 2003;  12 592-600
• 17 Piper C, Wiemer M, Schultheiß H P, Horstkotte D. Sinnvolle Diagnostik und Therapieplanung bei organischer und relativer Mitralklappeninsuffizienz.  Herz. 1998;  23 429-433
• 18 Preiss M, Bernet F, Zerkowski H R. Additional information from the GELIA database: analysis of benefit from self-management of oral anticoagulation (GELIA 6).  Eur Heart J Suppl. 2001;  3 (Suppl Q) Q50-Q53
• 19 Rahimtoola S H. Valvular heart disease: a perspective on the asymptomatic patient with severe valvular aortic stenosis.  Eur Heart J. 2008;  29 1783-1790
• 20 Rodewald G, Kalmar P. Cardiac surgery in the Federal Republic of Germany during 1985. A report by the German Society for Thoracic and Cardiovascular Surgery.  Thorac Cardiovasc Surgeon. 1986;  34 406-408
• 21 Salem D N, Stein P D, Al-Ahmad A. et al . Antithrombotic therapy in valvular heart disease – native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126 (Suppl) 457S-482S
• 22 Vahanian A, Cormier B, Jung B. Percutaneous transvenous mitral commissurotomy using the Inoue Balloon: International Experience.  Cath Cardiovasc Diagn. 1994;  Suppl 2 8-15
• 23 Vahanian A, Baumgartner H, Bax J. et al . Guidelines on the management of valvular heart disease. The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.  Eur Heart J. 2007;  28 230-268
• 24 Villari B, Vassalli G, Monrad E S. et al . Normalization of diastolic dysfunction in aortic stenosis late after valve replacement.  Circulation. 1995;  91 2353-8
• 25 Weber K T. Cardiac interstitium in health and disease: The fibrillar collagen network.  J Am Coll Cardiol. 1989;  13 1637-51